Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aerospan

AstraZeneca AZ

AZ severe asthma drug benralizumab backed by CHMP

The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma

- PMLiVE

Asthma: beyond the blue and the brown

Innovation in respiratory medicine

AstraZeneca AZ

Setback for AZ as tralokinumab flunks asthma trial

Puts more pressure on AZ’s benralizumab to reach its potential

- PMLiVE

GSK preps COPD filing for asthma pioneer Nucala

Moves despite reporting mixed data for the treatment earlier this year

- PMLiVE

GSK starts trial of Nucala to seek alternate indications

Asthma therapy drug to be used to target severe nasal polyposis

- PMLiVE

GSK’s Nucala posts mixed results in COPD

Conflicting late-stage trials throw doubt on its prospects

AstraZeneca AZ

AZ trial adds to pessimism about anti-IL-13 asthma drugs

Firm's IL-13 inhibitor failed to reduce the number of asthma attacks compared to placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

Stada opens books to let formal bidding commence

Cinven, Advent International and Bain Capital now have opportunity to revise their bids

- PMLiVE

Advent tops Cinven offer for Stada as third suitor looms

Values the OTC and generics specialist at €3.6bn, with offer open until 27 February

- PMLiVE

Allergan adds Zeltiq to M&A roster in $2.48n deal

Expands aesthetic pharma business with “best-in-class” body contouring system

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links